Clinical Trials Using SIRPa-Fc Fusion Protein TTI-621
Clinical trials are research studies that involve people. The clinical trials on this list are studying SIRPa-Fc Fusion Protein TTI-621. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a / 1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Location: 8 locations
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase. The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor activity of TTI-621 will be evaluated in combination with other anti-cancer agents or radiation.
Location: 4 locations